ReviewScience and technology of advanced materials2025
Thylakoids for enhanced photodynamic therapy in hypoxic tumours.
Review in Science and technology of advanced materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioinspired Artificial Bioenergetic Organelles: Design Principles, Nanofabrication and Therapeutic Translation.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Plant-Derived Thylakoids Potentiate Copper-Mediated Multimodal Cell Death via Hypoxia Alleviation for Synergistic Antitumor Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Harnessing nature's blueprint: Unlocking the potential of subcellular structure membrane-coated nanosystems for precision medicine.Bioactive materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current tumor therapies face significant limitations such as hypoxic microenvironments, systemic toxicity, and immunosuppression. Thylakoid-based nanomaterials strategically integrate the structural-functional properties of natural biological components with the versatility of nanotechnology. These biomaterials have garnered substantial scientific interest due to their promising therapeutic potential in oncology. Thylakoids perform essential biological functions including solar energy absorption, photolytic oxygen generation, and operation of photosynthetic electron transport chains. Harnessing thylakoid-specific photochemical properties through nanoscale hybridization offers an innovative paradigm for developing multifunctional platforms in oncotherapy. This review summarizes current challenges in tumor therapy and the advantages of thylakoid-based nanomaterials in addressing these limitations. We further examine recent advances in the engineering design of thylakoid-based nanomaterials and their therapeutic applications. Finally, we discuss existing challenges and future prospects in this field.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.